aticaprant

News

One of J&J's blockbuster depression hopes has flamed out

Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.

News

J&J shares data on would-be blockbuster antidepressant

Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial

News

Recordati gets €10.9bn takeover bid from private equity firm

Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks